middle.news
Radiopharm Theranostics Advances RAD101 Phase 3 Trial Planning with FDA Meeting Set
9:02am on Monday 17th of August, 2026 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Advances RAD101 Phase 3 Trial Planning with FDA Meeting Set
9:02am on Monday 17th of August, 2026 AEST
Key Points
Scheduled FDA End-of-Phase 2 meeting on October 1, 2026
RAD101 Phase 2b trial achieved 93% concordance with MRI
FDA Fast Track Designation secured for RAD101
Partnership with Siemens Healthineers for manufacturing and distribution
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE